China the third Asian market to issue Augmentin recall over plasticiser concerns
This article was originally published in Scrip
Executive Summary
China's State FDA has become the third regulator in Asia to issue a recall for GlaxoSmithKline's Augmentin (amoxicillin clavulanate) following the discovery of trace amounts of a plasticiser in an oral suspension formulation of the antibacterial.